The U.S. Food and Drug Administration (FDA) has officially reversed its earlier stance, agreeing to review Moderna’s messenger RNA (mRNA)…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands Compared
The relentless pursuit of efficiency and patient safety in healthcare has driven a significant transformation within pharmacy operations, making the…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics
OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…
Read More
Sai Life Sciences plans to recruit 700+ professionals in FY27 as Indian CRDMO demand accelerates
Sai Life Sciences, a prominent Contract Research, Development & Manufacturing Organization (CRDMO) based in Hyderabad, India, has announced an ambitious…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its investigational weight loss treatment, CagriSema,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…
Read More
Closing the Information Gap: ETH Zurich Team Integrates Function and Binding in One Drug Screening Assay
A groundbreaking collaborative effort between researchers at ETH Zurich and Karolinska Institutet has culminated in the development of a novel…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry faces a profound and escalating crisis marked by soaring costs, protracted timelines, and persistently high failure rates…
Read More
From list price to net price: How finance leaders decode real drug costs
In the intricate landscape of the healthcare industry, discussions surrounding drug pricing frequently commence and conclude with the list price.…
Read More
